Shows
OncoAlertThe OncoAlert 🚨Weekly Round Up May 15-22The OncoAlert🚨ROUND UP Now Out‼️ Covering May 15-22, 2025 REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/...⭐️Discussing✅Systemic tx for HR+/HER2- early stage and metastatic #BreastCancer✅Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized #ProstateCancer✅Characterization of Patients with Lymph Node Only Metastatic #UrothelialCarcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin vs Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial✅NO LIMIT Study: in Advanced Gastric or Esophagogastric Junction Cancer✅PRODIGE 29-UCGI 26 (NEOPAN)on #PancreaticCarcinomaand more.....2025-05-2203 min
OncoAlertOncology Here & Now (GU Oncology) Upper Tract Urothelial carcinoma with Dr. Barbara Melao & Dr. Philippe SpiesJoin our Urology colleagues, Dr. Melao and Dr. Spiess, as they discuss upper tract urothelial carcinoma—from risk stratification to management strategies in both low-risk and high-risk, high-grade settings. They’ll also explore long-term renal function outcomes, a topic on which Dr. Spiess has recently published.2025-05-2021 min
OncoAlertVJ OA Oncology Journal Club: Final Results of the APHINITY Breast Cancer Trial Presented at ESMO Breast 2025Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025.2025-05-1602 min
OncoAlertThe OncoAlert Weekly Round Up May 2-8, 2025Discussing:Association between risk-reducing surgeries and survival in young BRCA carriers with #BreastCancer DESTINY-Breast11 Update from IndustryPALMIRA in Breast #Cancer (Palbo rechallenge)PEACE V STORM in #Prostate CancerMAGNITUDE :Niraparib and Abiraterone Acetate plus Prednisone in Met CR Prostate CancerOS EGFR-mutant AdvancedNon-Small Cell #LungCancer Treated with 1L Osimertinib Cemiplimab monotherapy as 1L treatment of patients with brain metastases from advanced #NSCLC with PDL1 ≥50%Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine and more2025-05-0803 min
OncoAlertVJ/OA Oncology Journal Club (Breast Cancer): Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer with Dr. MagatonThis international retrospective cohort study evaluated the safety of assisted reproductive technology (ART) in BRCA1/2 carriers who conceived after a breast cancer diagnosis at age 40 or younger. Among 543 women, 107 conceived using ART and 436 conceived spontaneously. ART methods included oocyte/embryo cryopreservation, in vitro fertilization, ovulation induction, and oocyte donation. Patients who used ART were generally older, had more hormone receptor-positive tumors, and a longer interval from diagnosis to conception. After a median follow-up of 5.2 years post-conception, ART use was not associated with an increased risk of disease-free survival events, suggesting that ART is a safe option for pregnancy after...2025-05-0205 min
OncoAlertOncology Here & Now (General Cancer): Cancer Report to the Nation with Dr. Ahmedin Jemal & Dr. Gil MorganJoin Dr. Jemal & Dr Morgan as they discuss this report, a collaboration among major U.S. cancer surveillance organizations, presents the latest national data on cancer incidence and mortality. Using data from cancer registries and national vital statistics, the analysis shows that while overall cancer death rates have steadily declined over the past 20 years — including during the COVID-19 pandemic — the annual rate of decline has recently slowed. Cancer incidence rates remained stable among males and rose slightly among females over time, with a temporary dip across all groups in 2020 likely due to pandemic-related disruptions in healthcare acce...2025-04-2808 min
VJOncology PodcastVJOncoAlert Journal ClubIn this week’s podcast, we take you through the latest episodes of the VJOncoAlert Journal Club—a collaborative series from VJOncology and OncoAlert that brings together leading oncology experts to discuss the most impactful and practice-changing research in the field.
We are joined by Misty Shields, MD, PhD, from the Indiana University Simon Comprehensive Cancer Center in Indianapolis, IN, who discusses the latest updates in small cell lung cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute in London, UK, and Brian Rini, MD, FASCO, of Vanderbilt-Ingram Cancer Center in Nashville, TN, comment on the heal...2025-04-2521 min
VJOncology PodcastVJOncoAlert Journal ClubIn this week’s podcast, we take you through the latest episodes of the VJOncoAlert Journal Club—a collaborative series from VJOncology and OncoAlert that brings together leading oncology experts to discuss the most impactful and practice-changing research in the field.
We are joined by Misty Shields, MD, PhD, from the Indiana University Simon Comprehensive Cancer Center in Indianapolis, IN, who discusses the latest updates in small cell lung cancer. Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute in London, UK, and Brian Rini, MD, FASCO, of Vanderbilt-Ingram Cancer Center in Nashville, TN, comment on the heal...2025-04-2521 min
OncoAlertVJ/OA Oncology Journal Club (Pancreatic Cancer): Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy by Dr. Marsha ReyngoldCohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting...2025-04-2503 min
OncoAlertThe OncoAlert Weekly Round Up April 17-24, 2025The OncoAlertWeekly Round Up Covering the TOP of the week April 18-24, 2025 REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration Discussing:UPDATE on DESTINY-Breast09https://astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.htmlUPDATE on ASCENT 04https://gilead.com/news/news-details/2025/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-tripAnnual Report to the Nationon the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemichttps://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35833Osimertinib vs. Afatinib in 1L therapy of atypi...2025-04-2405 min
OncoAlertVJ/OA Oncology Journal Club (Breast Cancer): Prognostic implications of risk definitions from monarchE & NATALEE by Dr. AreccoStudy compared the prognostic impact of differing high-risk inclusion criteria used in the monarchE and NATALEE trials among patients with hormone receptor-positive/HER2-negative early #BreastCancer , using data from the MIG1, GIM2, and GIM3 trials. Patients were stratified into high- and low-risk cohorts per each trial’s criteria, and further grouped into concordant low-risk, discordant risk, and concordant high-risk categories.Link to Articlehttps://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette2025-04-1604 min
OncoAlertOncology Here & Now (Lung Cancer): Dr. Marcelo Corassa & Dr. Biaggio Ricciuti discuss FLAURA, MARIPOSA & FLAURA2Oncology here & nowIn this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.Join Us2025-04-1420 min
OncoAlertVJ/OA Oncology Journal Club: SANO Trial with Dr. van der Wilk (Oesophageal Cancer)Dr. van der Wilk dives into the results of the SANO Trial in Oesophageal Cancer and recently published on the Lancet Oncology. The phase 3 trial investigated whether active surveillance could be a non-inferior alternative to standard surgery in individuals with oesophageal cancer who achieved a clinical complete response after neoadjuvant chemoradiotherapy. Conducted in 12 Dutch hospitals, the study randomized 309 participants to either active surveillance or standard oesophagectomy. After a median follow-up of 38 months, the 2-year overall survival for active surveillance (74%) was non-inferior to that of standard surgery (71%), with no significant differences in postoperative complications or mortality between groups. T...2025-04-1106 min
OncoAlertThe OncoAlert Weekly Round Up Covering April 4-10, 2025Dear Colleagues,Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:Prognostic implications of risk definitions from the monarchE and NATALEE trialhttps://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignetteEvaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancerhttps://link.springer.com/article/10.1007/s10549-025-07685-8?utm...2025-04-1103 min
OncoAlertVJ/OA Journal Club: LITESPARK 005 with Dr. Brian Rini & Dr. Tom Powles (KidneyCancer)The phase 3 LITESPARK-005 trial evaluated patient-reported outcomes (PROs) for belzutifan, a HIF-2α inhibitor, versus everolimus in patients with advanced renal cell carcinoma previously treated with immune checkpoint and anti-angiogenic therapy. 2025-04-0306 min
OncoAlertOncology Here & Now: Dr. Joe McCollom & Dr. Cristiane Bergerot Discuss Telemedicine & Supportive CareOncology Here & NowIn this interview, OncoAlert faculty members Dr. Joseph McCollom from Parkview Health (USA) and Dr. Cristiane Bergerot from OncoClinicas (Brazil) explore supportive care and the future of telemedicine. Their discussion spans the evolution of telehealth—from its pivotal role during the pandemic to its current applications—and what lies ahead.Join us for this insightful conversation!2025-03-2615 min
OncoAlertVJ/OA Journal Club: Dr. Misty Shields with the TOP Advances in Small Cell Lung CancerDr. Misty Shields guides us through this great paper out on Cancer (ACS) on the TOP advances in Small Cell Lung Cancer. Small cell lung cancer (SCLC) remains a leading cause of cancer mortality, with its aggressive nature and frequent relapse leading to poor outcomes. In recent years, immunotherapy has provided some survival benefits, and in 2024, key breakthroughs have significantly improved patient outcomes. Notable advances include the use of consolidative durvalumab immunotherapy for limited-stage SCLC, new insights into timing immunotherapy with radiation, and promising treatments such as the bispecific T-cell engager tarlatamab and antibody-drug conjugates. Precision medicine approaches, like...2025-03-2504 min
OncoAlertOncology Here & Now: Dr. Maryam Lustberg & Dr. Elisa Agostinetto discuss CDK4/6 inh in Breast cancerOncology Here & NowIn this interview, Dr. Elisa Agostinetto from the Jules Bordet Institute in Belgium speaks with Dr. Maryam Lustberg from Yale Cancer Center. Together, they dive deep into the use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer. Their discussion covers the use of Abemaciclib and Ribociclib following the monarchE and NATALEE trials, applications in the treatment of male breast cancer, and much more.Join us!2025-03-1415 min
OncoAlertOncology Here & Now: Drs. Silke Gillessen & Aurelius Omlin of APCCC discuss Prostate Cancer, Hot Topics, APCCC & The Need for Consensus meetingsIn this interview with Dr. Silke Gillessen & Dr. Aurelius Omlin , we delve into the origins, Topics and evolution of the Advanced #ProstateCancer Consensus Conference@APCCC_Lugano began in 2015 to address critical questions in prostate cancer management where evidence is lacking or conflicting. Over the years, the conference has focused on various evolving topics, such as oligometastatic disease, treatment sequencing, and new imaging technologies. The 2024 APCCC highlighted major discussions on next-generation imaging, genomic biomarkers, and diagnostic challenges, with a strong emphasis on the need to balance cutting-edge technology with clinical practicality.2025-03-0506 min
GU Cast | Urology PodcastAll your GU Highlights from #ESMO24!Ask anyone which big oncology meeting gave us the best GU oncology highlights this year and the answer is easy! ESMO24 in Barcelona! Jammed full of key papers and so many highlights, Declan and Renu bring you a great overview in this GU Cast Conference Highlights from ESMO24. Listen to discussions with investigators and key opinion leaders, interviews with delegates, a fun speed-walk through the prostate cancer poster session, and a fun morning at the OncoAlert 5K.GU Cast Conference Highlights ares supported by our Conference Highlights Partner, Bayer China. Even better on our...2024-10-0754 min
GU Cast | Urology PodcastUro-Podcasters Love-in in Lugano!!Great fun on the shores of Lake Lugano where the hosts of three of the best-known podcasts in GU Oncology get together for a chat! Declan and Renu from GU Cast, join with Brian and Tom from Uromigos, and Gill from Oncoalert. How did it all start? Why did it all start?! Best moments, worst moments etc. Tune if for a chat, and do please subscribe/like/follow all of us! Just search GU Cast/Uromigos/Oncoalert wherever you get your podcasts 2024-04-2716 min
Осторожно: утро!Спецоперация в Украине. Новости утра 28 февраля• Переговоры между Россией и Украиной должны пройти сегодня в Гомельской области.• Мэр Купянска Харьковской области пошел на сотрудничество с российскими войсками. Украинские власти обвинили его в госизмене.• Минобороны РФ и МВД Украины дают разные оценки числа погибших и раненных. • Минобороны РФ обвинило Украину в применении фосфора.• В аэропорту Гостомель сожгли самый большой самолет в истории Ан-225 «Мрия».• Украина выпускает из мест лишения свободы заключенных с военным опытом.• По данным ООН, за последнее время в Европу из Украины выехало около 360 тысяч мирных жителей.• Рамзан Кадыров публично призвал Путина к решительному штурму. В спор с ним вступил Михаил Ходорковский.• Владимир Путин приказал перевести силы сдерживания в особый режим.• На выходных в России продолжались антивоенные акции протеста. С начала спецоперации на них задержали более 6 тысяч человек.• В Беларуси прошел референдум по поправкам к Конституции. По предварительным данным, 65,16% поддержали поправки.• ЕС и Канада закрыли воздушное пространство для России.• ЕС заморозил около половины финансовых резервов России. Часть российских банков отключат от SWIFT.• ЕС предоставит Украине оружие на 450 млн евро.• ООН собирает чрезвычайную специальную Генассамблею впервые за десятилетия.• Украину могут включить в ЕС.• Австралия ввела санкции против Путина, Лаврова, Мишустина и ряда российских чиновников.• Службы доставки UPS и FedEx прекращает работу в России.• British Petroleum откажется от 19,5% акций Роснефти.• Всемирная сеть онкологов OncoAlert прекратила сотрудничество с Россией.• ФИФА отменила проведение матчей сборных на территории России. Футбольная ассоциация Англии отказалась играть с командами России. • Международная ассоциация самбо приостановила проведение соревнований на территории России и Беларуси, а Международная ассоциация дзюдо лишила Путина статуса почетного президента.• Депутат Госдумы от КПРФ Вячеслав Мархаев заявил, что осуждает руководство России за ведение спецоперации в Украине.• Коллективное письмо против спецоперации подписали более 200 муниципальных депутатов.• По словам юриста Павла Чикова, в Москве начали задерживать и опрашивать граждан Украины.Больше новостей — в телеграм-канале наших коллег «Осторожно, новости» https://t.me/ostorozhno_novostiБудьте в курсе событий!Наш Instagram — https://www.instagram.com/ostorozhno_podcastsTelegram — https://t.me/ostorozhno_podcastsTelegram-канал «Кровавая барыня» — https://t.me/bloodysx2022-02-2802 min
Oncology SpotlightSpotlight With Dr Gil MorganToday's Oncology Spotlight is with Dr. Gil Morgan, Medical Oncologist at Skåne University Hospital in Lund, Sweden, and the founder of OncoAlert.
Know more about Dr. Gil Morgan:
Twitter: https://twitter.com/weoncologists
LinkedIn: https://www.linkedin.com/in/gil-morga...
Know more about OncoAlert:
Twitter: https://twitter.com/OncoAlert
LinkedIn: https://www.linkedin.com/company/onco...
For inquiries, contact us at info@oncoassist.com
Let's connect:
Website: www.oncoassist.com
Twitter: https://twitter.com/oncoassist
LinkedIn: https://www.linkedin.com/showcase/onc...
Instagram:https://www.instagram.com/oncoassist/
Facebook: https://www.facebook.com/ONCOassist2021-07-2838 min
Oncology SpotlightOncology Spotlight With Dr. Giuseppe BannaToday's Oncology Spotlight is with Dr. Giuseppe Banna, a 46-year old Consultant Medical Oncologist, and father of 2 daughters. His clinical and scientific experience has been mostly focused on thoracic and urology cancer and prognostic and predictive biomarkers for systemic cancer treatments, particularly for immunotherapy. He works at the Department of Oncology of Portsmouth Hospitals University NHS Trust in the UK and his subspecialties are Lung and Urology. He’s Italian and moved to the UK two years ago.
Currently, he’s working with his European colleagues on predictive models of efficacy and toxicity of immunotherapy based on immune-inflammatory biomarkers and arti...2021-06-0931 min
Beyond the JournalDr. Gil Morgan, on OncoAlert and Developing a Global Online Cancer Community | BTJ-002We chat with Dr. Gil Morgan, Medical Oncologist at Skåne University Hospital in Lund, Sweden and founder of Cancer News Service OncoAlert, to discuss the genesis of OncoAlert and how it has helped to cultivate a greater sense of an international oncology community through digital education.2020-11-1700 min
Beyond the Journal (Audio)Dr. Gil Morgan, on OncoAlert and Developing a Global Online Cancer Community | BTJ-002We chat with Dr. Gil Morgan, Medical Oncologist at Skåne University Hospital in Lund, Sweden and founder of Cancer News Service OncoAlert, to discuss the genesis of OncoAlert and how it has helped to cultivate a greater sense of an international oncology community through digital education.2020-11-1748 minVJOncology PodcastThe ONS/EONS Congress Roundtable Discussion with VJOncology and OncoAlertThe treatment of cancer continues to evolve rapidly, with expanded therapeutic options and changes to clinical practice. Additionally, the care of patients with cancer has been complicated in 2020 by the COVID-19 pandemic. Oncology nurses are at the forefront of cancer care, looking after patients and their carers day-to-day. It is therefore vital to share information and educate nurses to maintain their knowledge and skills, to ensure the best care for their patients.
In this podcast, Gilberto Morgan, MD, Skåne University Hospital, Lund, Sweden, chairs a thoughtful discussion with Darcy Burbage, DNP, RN, AOCN, CBCN, Oncology Clinical N...2020-09-1047 minVJOncology PodcastThe ONS/EONS Congress Roundtable Discussion with VJOncology and OncoAlertThe treatment of cancer continues to evolve rapidly, with expanded therapeutic options and changes to clinical practice. Additionally, the care...
The post The ONS/EONS Congress Roundtable Discussion with VJOncology and OncoAlert appeared first on VJOncology.
2020-09-1047 min